EUVIMEDEUVIMED entdecken
Crossref

Characterizing How Sponsor Companies are Operationalizing the Transition from Traditional to Risk-Based and Centralized Monitoring in Clinical Trials

Hana Do, Beth Harper, Julie S. Appel, Andrzej Kinasiewicz, Miguel Valenzuela, Joanne Benedict, Kenneth Getz

Therapeutic Innovation & Regulatory Science · 19.11.2026

DOI: 10.1007/s43441-026-01072-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 19.11.2026. Verfasst von Hana Do und 6 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Do, H., Harper, B., Appel, J. S., Kinasiewicz, A., Valenzuela, M., Benedict, J., & Getz, K. (2026). Characterizing How Sponsor Companies are Operationalizing the Transition from Traditional to Risk-Based and Centralized Monitoring in Clinical Trials. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-026-01072-1

Vancouver

Do H, Harper B, Appel JS, Kinasiewicz A, Valenzuela M, Benedict J, et al. Characterizing How Sponsor Companies are Operationalizing the Transition from Traditional to Risk-Based and Centralized Monitoring in Clinical Trials. Therapeutic Innovation & Regulatory Science. 2026. doi:10.1007/s43441-026-01072-1

BibTeX
@article{Do2026,
  author = {Do, Hana and Harper, Beth and Appel, Julie S. and Kinasiewicz, Andrzej and Valenzuela, Miguel and Benedict, Joanne and Getz, Kenneth},
  title = {Characterizing How Sponsor Companies are Operationalizing the Transition from Traditional to Risk-Based and Centralized Monitoring in Clinical Trials},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  doi = {10.1007/s43441-026-01072-1}
}
Kostenlos starten →